The future of targeted therapies in ovarian cancer

Oncologist

Volumn 14, Issue 7, 2009, Pages 706-716

  Banerjee, Susana ^a   Gore, Martin ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Ovarian cancer; PARP inhibitors; Targeted therapy; VEGF inhibitors

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; AZD 2281; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IMC 1121B; INTERFERON; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PLACEBO; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ANGIOGENESIS; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DNA REPAIR; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL OBSTRUCTION; GENE MUTATION; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CANCER; LEUKOPENIA; LUNG CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEINURIA; REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; UTERUS CANCER; VEIN THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; FEMALE; HUMANS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68449084674     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0013     Document Type: Review

References (82)

1. Cancer Research UK. UKOvarian Cancer Incidence Statistics. Available at http://info.cancerresearchuk.org/cancerstats/types/ovary/incidence, accessed May 26, 2009.
2. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
3. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-974.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
5. Spannuth WA, Nick AM, Jennings NB et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2009;124:1045-1053.
6. Boocock CA, Charnock-Jones DS, Sharkey AM et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506-516.
7. Sher I, Adham SA, Petrik J et al. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 2009;124: 553-561.
8. Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-591.
9. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
10. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
11. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
12. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:Arandomized phase III study. J Clin Oncol 2008;26:2013-2019.
13. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
14. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-2111. (Pubitemid 350296300)
15. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. (Pubitemid 46089672)
16. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
17. Paley PJ, Staskus KA, Gebhard K et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98-106. (Pubitemid 27270925)
18. Shen GH, Ghazizadeh M, Kawanami O et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000;83:196-203. (Pubitemid 30411717)
19. Cooper BC, Ritchie JM, Broghammer CL et al. Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer. Clin Cancer Res 2002;8:3193-3197. (Pubitemid 35155030)
20. Hefler LA, Zeillinger R, Grimm C et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 2006;103:512-517. (Pubitemid 44740099)
21. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-1256. (Pubitemid 28465848)
22. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-5186. (Pubitemid 350232248)
23. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer:A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-5171. (Pubitemid 350237599)
24. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
25. Micha JP, Goldstein BH, Rettenmaier MA et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007;17:771-776.
26. Chura JC, Van Iseghem K, Downs LS Jr et al. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007;107:326-330. (Pubitemid 47575735)
27. McGonigle KF, Muntz HG, Vuky JL et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC) [abstract 5551]. J Clin Oncol 2008;26:305s.
28. Schultheis AM, Lurje G, Rhodes KE et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008;14:7554-7563.
29. Cobleigh MA, Langmuir VK, SledgeGWet al.Aphase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(suppl 16):117-124.
30. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
31. Nimeiri HS, Oza AM, Morgan RJ et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008;110:49-55.
32. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007;105:3-6. (Pubitemid 46441477)
33. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69(suppl 3):25-33. (Pubitemid 41680950)
34. Byrne AT, Ross L, Holash J et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-5728. (Pubitemid 37499496)
35. Hu L, Hofmann J, Holash J et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005;11:6966-6971. (Pubitemid 41428755)
36. Tew WP, Colombo N, Ray-Coquard I et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 2007;25(18 suppl):Abstract 5508.
37. Welch S, Hirte H, Elit L et al. CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-a trial of the PMH Phase II Consortium. J Clin Oncol 2007; 25(18 suppl):Abstract 5519.
38. Matei D, Sill W, DeGeest K et al. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2008; 26(15 suppl):Abstract 5537.
39. Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-3714.
40. Friedlander M, Hancock KC, Benigno B et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study. J Clin Oncol 2007;25(18 suppl):Abstract 5561.
41. Matulonis UA, Berlin ST, Krasner CN et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 2008;26(15 suppl):Abstract 5501.
42. Hirte H, Vidal L, Fleming GF et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008;26(15 suppl):Abstract 5521.
43. Dempke WC, Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 2009;45:1117-1128.
44. Ledermann JA, Rustin GJ, Hackshaw A et al. A randomized phase II placebo- controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 2009;27(15 suppl):Abstract 5501.
45. Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double strand break repair. J Clin Oncol 2008;26:3785-3790.
46. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008;8:363-369.
47. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-917. (Pubitemid 40559005)
48. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921. (Pubitemid 40559006)
49. Audeh MW, Penson RT, Friedlander M et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009;27(15 suppl):Abstract 5500.
50. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-819.
51. Jacinto FV, Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 2007;22:247-253. (Pubitemid 47216613)
52. Baldwin RL, Nemeth E, Tran H et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res 2000; 60:5329-5333. (Pubitemid 30761235)
53. Press JZ, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17. (Pubitemid 351279967)
54. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672. (Pubitemid 41464705)
55. Takai N, Jain A, Kawamata N et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005;104:2701-2708. (Pubitemid 41798280)
56. Campiglio M, Ali S, Knyazev PG et al. Characteristics of EGFR familymediated HRG signals in human ovarian cancer. J Cell Biochem 1999;73: 522-532. (Pubitemid 29256941)
57. Sewell JM, Macleod KG, Ritchie A et al. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). Br J Cancer 2002;86:456-462.
58. del Carmen MG, Rizvi I, Chang Y et al. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst 2005;97:1516-1524. (Pubitemid 41631951)
59. Reibenwein J, Krainer M. Targeting signaling pathways in ovarian cancer. Expert Opin Ther Targets 2008;12:353-365.
60. Serrano-Olvera A, Dueñas-Gonzalez A, Gallardo-Rincón D et al. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006;32:180-190.
61. Cloven NG, Kyshtoobayeva A, Burger RA et al. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 2004;92:160-166. (Pubitemid 38147385)
62. Bartlett JM, Langdon SP, Simpson BJ et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996;73:301-306. (Pubitemid 26047507)
63. Tanner B, Kreutz E, Weikel W et al. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol Oncol 1996;62:268-277. (Pubitemid 26274810)
64. Felip E, Del Campo JM, Rubio D et al. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 1995;75:2147-2152.
65. Gordon AN, Finkler N, Edwards RP et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. Int J Gynecol Cancer 2005;15:785-792. (Pubitemid 41783082)
66. Schilder RJ, Sill MW, Chen X et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression:AGynecologic Oncology Group study. Clin Cancer Res 2005;11:5539-5548. (Pubitemid 41060831)
67. Wagner U, du Bois A, Pfisterer J et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinumtaxane based therapy-a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007;105:132-137. (Pubitemid 46441449)
68. Posadas EM, Liel MS, Kwitkowski V et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007;109:1323-1330. (Pubitemid 46466559)
69. Bookman MA, Darcy KM, Clarke-Pearson D et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2:Aphase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-290. (Pubitemid 46606157)
70. Gordon MS, Matei D, Aghajanian C et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-4332. (Pubitemid 46630791)
71. Makhija S, Glenn D, Ueland F et al. Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol 2007; 25(18 suppl):Abstract 5507.
72. Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2001;(1):CD001034.
73. Tchekmedyian NS, Liem AK, Quan ET et al. Aromatase inhibitor therapy for estrogen receptor positive ovarian cancer. J Clin Oncol 2006;24(18 suppl):Abstract 15038.
74. Bowman A, Gabra H, Langdon SP et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002;8:2233-2239. (Pubitemid 34753595)
75. Smyth JF, Gourley C, Walker G et al. Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptorpositive patients. Clin Cancer Res 2007;13:3617-3622. (Pubitemid 46955124)
76. Verma S, Alhayki M, Le T et al. Phase II study of exemestane (E) in refractory ovarian cancer (ROC). J Clin Oncol 2006;24(18 suppl):Abstract 5026.
77. Kavanagh JJ, Hu W, Fu S et al. Anti-tumor activity of letrozole in patients with recurrent advanced low malignant potential or low-grade serous ovarian tumors. J Clin Oncol 2007;25(18 suppl):Abstract 5582.
78. Papadimitriou CA, Markaki S, Siapkaras J et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004;66:112-117. (Pubitemid 38608377)
79. Oei AL, Sweep FC, Thomas CM et al. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Int J Oncol 2008;32: 1145-1157.
80. Berek J, Taylor P, McGuire W et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009;27:418-425.
81. Jubb AM, Oates AJ, Holden S et al. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006;6:626-635. (Pubitemid 44140860)
82. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.